Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Funding ended

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Metastatic Triple-Negative Breast Carcinoma
Unresectable Triple-Negative Breast Carcinoma

Interventions

PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
DRUG: Celecoxib
PROCEDURE: Computed Tomography
BIOLOGICAL: Interferon Alpha-2
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Pembrolizumab
DRUG: Rintatolimod

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]